Literature DB >> 19230645

Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities.

Patricia Volkow1, Kimberly C Brouwer, Oralia Loza, Rebeca Ramos, Remedios Lozada, Richard S Garfein, Carlos Magis-Rodriguez, Michelle Firestone-Cruz, Steffanie A Strathdee.   

Abstract

OBJECTIVE: Paid plasma donation has contributed to HIV epidemics in many countries. Eleven million liters of plasma are fractionated annually in the U.S., mainly from paid donors. Deferral of high-risk donors such as injection drug users (IDUs) is required for paid donations. We studied circumstances surrounding paid plasma donation among IDUs in two Mexico-U.S. border cities.
METHODS: In 2005, IDUs > or = 18 years old in Tijuana (N=222) and Cd. Juarez (N=206) who injected in the last month were recruited through respondent-driven sampling. Subjects underwent antibody testing for HIV and HCV and an interviewer-administered survey including questions on donating and selling whole blood and plasma.
RESULTS: Of 428 IDUs, HIV and HCV prevalence were 3% and 96%, respectively; 75 (17.5%) reported ever having donated/sold their blood or plasma, of whom 28 (37%) had sold their plasma for an average of $16 USD. The majority of IDUs selling plasma were residents of Ciudad Juarez (82%); 93% had sold their plasma only in the U.S. The last time they sold their plasma, 65% of IDUs had been asked if they injected drugs. Although the median time since last selling plasma was 13 years ago, 3 had done so within the prior 2 years, one within the prior 6 months; of these 3 IDUs, 2 were from Cd. Juarez, one from Tijuana; all 3 had only sold their plasma in the U.S.
CONCLUSIONS: Although selling plasma appears uncommon among IDUs in these two Mexican border cities, the majority sold plasma in the U.S. and only one-third were deferred as high-risk donors. Paying donors for plasma should be a matter of public inquiry to encourage strict compliance with regulations. Plasma clinics should defer donors not only on behavioral risks, but should specifically inspect for injection stigmata.

Entities:  

Mesh:

Year:  2009        PMID: 19230645      PMCID: PMC2955515          DOI: 10.1016/j.drugpo.2008.12.006

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  30 in total

1.  Geographic location of commercial plasma donation clinics in the United States, 1980-1995.

Authors:  Robert C James; Cameron A Mustard
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

2.  LAV/HTLV-III seroconversion and disease in hemophiliacs treated in France.

Authors:  D Mathez; J Leibovitch; Y Sultan; P Maisonneuve
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

3.  Seroconversion for HTLV-III since 1980 in British haemophiliacs.

Authors:  S J Machin; B A McVerry; R Cheingsong-Popov; R S Tedder
Journal:  Lancet       Date:  1985-02-09       Impact factor: 79.321

4.  Differential prevalence of antibody to AIDS-associated retrovirus in haemophiliacs treated with Factor VIII concentrate versus cryoprecipitate: recovery of infectious virus.

Authors:  M A Koerper; L S Kaminsky; J A Levy
Journal:  Lancet       Date:  1985-02-02       Impact factor: 79.321

5.  HTLV-III antibody in sequential plasma samples: from haemophiliacs 1974-84.

Authors:  R Madhok; M Melbye; G D Lowe; C D Forbes; K S Froebel; A J Bodner; R J Biggar
Journal:  Lancet       Date:  1985-03-02       Impact factor: 79.321

6.  Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate.

Authors:  J J Goedert; M G Sarngadharan; M E Eyster; S H Weiss; A J Bodner; R C Gallo; W A Blattner
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

7.  Parvovirus B19 transmission by heat-treated clotting factor concentrates.

Authors:  Johannes Blümel; Ivo Schmidt; Wolfgang Effenberger; Holger Seitz; Hannelore Willkommen; Hans Herrmann Brackmann; Johannes Löwer; Anna Maria Eis-Hübinger
Journal:  Transfusion       Date:  2002-11       Impact factor: 3.157

8.  Commercial factor VIII associated hepatitis, 1974-75, in the United Kingdom: a retrospective survey.

Authors:  J Craske; P Kirk; B Cohen; E M Vandervelde
Journal:  J Hyg (Lond)       Date:  1978-06

9.  HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA.

Authors:  M Melbye; K S Froebel; R Madhok; R J Biggar; P S Sarin; S Stenbjerg; G D Lowe; C D Forbes; J J Goedert; R C Gallo
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

10.  Epidemic hepatitis B caused by commercial human immunoglobulin.

Authors:  T J John; G T Ninan; M S Rajagopalan; F John; T H Flewett; D P Francis; A J Zuckerman
Journal:  Lancet       Date:  1979-05-19       Impact factor: 79.321

View more
  2 in total

1.  High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.

Authors:  Hui Li; Katharine J Bar; Shuyi Wang; Julie M Decker; Yalu Chen; Chuanxi Sun; Jesus F Salazar-Gonzalez; Maria G Salazar; Gerald H Learn; Charity J Morgan; Joseph E Schumacher; Peter Hraber; Elena E Giorgi; Tanmoy Bhattacharya; Bette T Korber; Alan S Perelson; Joseph J Eron; Myron S Cohen; Charles B Hicks; Barton F Haynes; Martin Markowitz; Brandon F Keele; Beatrice H Hahn; George M Shaw
Journal:  PLoS Pathog       Date:  2010-05-13       Impact factor: 6.823

2.  Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing.

Authors:  Hui Li; Mark B Stoddard; Shuyi Wang; Lily M Blair; Elena E Giorgi; Erica H Parrish; Gerald H Learn; Peter Hraber; Paul A Goepfert; Michael S Saag; Thomas N Denny; Barton F Haynes; Beatrice H Hahn; Ruy M Ribeiro; Alan S Perelson; Bette T Korber; Tanmoy Bhattacharya; George M Shaw
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.